Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Sidley Austin says it published updated life sciences contingent value rights research
Sidley Austin said it published updated research on contingent value rights in public life sciences transactions through the first half of 2026. The firm said 28 of 59 transactions announced in 2025 included a CVR, a 47% share and the highest annual proportion in its survey.
Key points
- Sidley Austin said its dataset extends back to 2018.Sidley Austin
- The firm said nearly 40% of surveyed CVR deals above $1 billion arose in 2025 and the first half of 2026.Sidley Austin
- Sidley Austin said CVRs appeared in more than half of announced public biopharma deals in 2025.Sidley Austin
- The firm said the research examines post-closing efforts provisions and other contractual terms.Sidley Austin